An MDMA-assisted therapy session is a structured 6–8 hour clinical day, repeated three times across a ~12-week program. Each dosing day is bookended by preparation sessions before and integration sessions after. Most patients arriving for their first session have read about the medicine but want to know what the day actually looks like — what to wear, what to bring, what the dosing room looks like, what the peak feels like, when they can go home, and what the next day is like. A distinctive feature of MDMA-AT versus psilocybin or ketamine therapy: patients typically remain conversationally available and emotionally engaged during the peak, which means the dosing session involves active trauma-focused therapeutic work rather than predominantly inward experience. Some Lykos Phase 3 protocols included overnight stays at clinic after the first dose for additional monitoring. This article walks through it in the order it happens, drawing on published trial protocols (Mitchell 2021/2023, Mithoefer 2018) and on the standards used by SAP-pathway Canadian providers.
Key takeaways
- The dosing day is 6–8 hours total in clinic — arrival, vitals, dosing, peak (1.5–3 hours), comedown, recovery, discharge.
- Onset is 30–60 minutes after taking the dose. Peak intensity is at 1.5–3 hours. Effects resolve over 4–6 hours total.
- Two trained therapists are present during dosing in MAPS-supported protocols. The therapy team is actively engaged in conversation during the peak — distinctive from psilocybin or ketamine sessions where therapists are predominantly quiet.
- You typically remain conversationally available during the peak — emotional warmth and reduced fear allow active trauma-focused therapeutic work, sometimes called the "extended therapeutic window."
- You cannot drive home. Designated driver required. Some protocols include overnight clinic stays after the first dose.
- Common physical sensations: pupil dilation, mild blood pressure and heart rate elevation, body temperature increase, jaw clenching, mild nausea early.
- Common experiential phenomena: emotional warmth, relational openness, reduced fear of vulnerability, increased empathy, conversational availability — not classic psychedelic visuals or ego dissolution.
- Three dosing sessions across ~12 weeks, with preparation and integration sessions before and after each — total ~24 sessions across the full program.
Before the day — preparation
Preparation begins 4–6 weeks before the first dosing session, with 3 dedicated preparation sessions with your therapy team. By the time the dosing day arrives:
- You have met the therapy team who will be present during all three dosing sessions
- Reviewed your trauma history and intentions
- Practiced grounding skills for navigating moments of distress
- Signed informed consent including off-label / SAP framing, expected effects, known risks
- Arranged a designated driver (or arranged overnight stay if your protocol includes one)
- Planned post-session rest for the remainder of the day and the days following
For the therapeutic-frame deep dive, see What Is MDMA-Assisted Therapy?.
Day-before prep
The 24 hours before dosing typically include:
- Light meal in the evening; light breakfast on the day if instructed
- Avoid alcohol, cannabis, recreational substances for 24+ hours before
- Hold specific medications under prescriber supervision — most protocols taper SSRIs/SNRIs before MDMA dosing; benzodiazepines may be held on dosing day; MAOIs are absolute exclusion (washout completed in advance)
- Sleep well
- Bring the day's items: a comfortable change of clothes, a journal, water bottle (electrolyte-balanced often provided in clinic), perhaps a meaningful object
Arrival — the first ~15 minutes
You arrive at the clinic in the morning. Standard elements:
- Check-in and orientation to the dosing room — typically aesthetically curated, soft lighting, comfortable couch or bed, blanket
- Confirmation of designated driver (and overnight stay if applicable)
- Final medical review: blood pressure (both arms), heart rate, oxygen saturation, ECG if not on file. Cardiovascular monitoring is more intensive than psilocybin or ketamine sessions because of MDMA's pronounced sympathomimetic effects.
- Final review of consent and review of the day
- Settling in with comfortable clothes, blanket, water available
The room is warm, softly lit, aesthetically calming. Some protocols use small touches that support emotional safety — fresh flowers, art, family photos available if the patient wants them nearby.
Dose administration
The dose is taken orally — typically 80 mg MDMA as the initial dose, with an optional 40 mg booster ~90 minutes later if appropriate per the Mitchell 2021/2023 protocol. Your specific dose depends on your SAP-authorized protocol.
Dose administration takes a few minutes. After taking the dose, you settle into the dosing position — usually reclining on a couch or bed, with music available.
Onset (30–60 minutes after dose)
Effects begin gradually. The first awareness:
- Mild emotional warmth beginning to emerge
- Body sensations — slight changes in body temperature, mild jaw tension
- Subtle perceptual shifts — colours feel slightly more vivid; ambient sounds feel more present (much milder than classic psychedelic visual changes)
- Increased openness beginning to surface
The therapy team is gently present during onset, beginning to engage with the patient as effects build.
Peak (1.5–3 hours after dose)
This is the most intense and therapeutically active phase. Distinctive features of the MDMA peak:
- Emotional warmth and openness — often described as feeling unusually connected, generous, vulnerable, undefended
- Reduced fear of vulnerability — willingness to discuss content that would normally feel too threatening
- Increased empathy for self and others
- Sense of safety even when engaging with traumatic content
- Conversational availability — patients usually remain able to talk, reflect, narrate. This is fundamentally different from the inward-focused psilocybin experience or the dissociated ketamine experience.
- Pupil dilation, body temperature elevation, mild blood pressure and heart rate elevation — all clinically monitored
- Jaw clenching — common; mouth guards available in some protocols
The therapy team is actively engaged during the peak. This is the "extended therapeutic window" — the patient's emotional warmth and reduced amygdala reactivity to threat cues allow active trauma-focused therapeutic work that conventional psychotherapy or other psychedelic-assisted models may not enable. The team conducts narrative reconstruction, attachment work, fear-extinction work, and meaning-making in real time.
For the therapeutic-frame detail, see What Is MDMA-Assisted Therapy?.
Comedown (3–5 hours after dose)
The intensity gradually subsides. Common features:
- Continued emotional openness with declining intensity
- Patient often spontaneously continues meaning-making — articulating what came up, what felt important, what was unexpected
- Physical settling — heart rate and blood pressure return to baseline; jaw tension resolves
- Fatigue — emotional and physical
- Often hungry — light food typically available
The therapy team supports light initial integration — capturing themes, emotions, narrative content. Deeper integration is for the structured integration sessions in the days following.
Discharge or overnight stay (~6–8 hours after arrival)
Standard discharge elements:
- Final vitals check: BP, HR, body temperature
- Confirmation of stable mental status: oriented, communicative, not acutely distressed
- Brief debrief and integration session scheduling
- Designated driver pickup OR overnight stay arrangements
Overnight clinic stays were a feature of some Lykos Phase 3 protocols, particularly after the first dose, to allow staff to monitor for any acute issues during recovery sleep. Specific Canadian SAP-pathway protocols vary; confirm with your clinical team whether your protocol includes overnight stays.
If discharged: you leave clinic 6–8 hours after arrival with your designated driver.
At home — the rest of the day
The remainder of the dosing day is rest. Standard guidance:
- No driving for at least 24 hours
- No alcohol, cannabis, or recreational substances for at least 24 hours (some protocols specify longer)
- Light food and electrolyte hydration (avoid plain-water excess given hyponatremia risk)
- Quiet activity — many patients journal; some prefer silence; some watch nature
- Avoid major decisions for the next 24 hours
- Avoid intensive exercise for 24–48 hours
The day after and the week ahead
Most patients describe the day after as a period of continued emotional openness with significant fatigue. Common features of the post-dosing recovery period:
- Day 1 (24 hrs after): tired but emotionally open; integration session typically scheduled within 24–72 hours
- Days 2–4: gradual energy recovery; some patients experience the "midweek blues" — mild low mood as serotonin replenishes
- Days 5–7: energy normalizes; mood stabilizes
- Week 2: integration sessions continue; trauma processing continues
- Weeks 3–5: 2nd dosing session typically scheduled; preparation session before
- Weeks 8–10: 3rd dosing session
- Weeks 11–12+: final integration sessions
Across the full ~12-week program, patients have ~24 clinical contacts (3 preparation + 3 dosing + 9 integration + ~6 additional check-ins or extended integration depending on protocol).
What's normal versus what to flag
Normal during and after the session:
- Emotional warmth, openness, increased connection
- Mild blood pressure and heart rate elevation
- Body temperature elevation (managed)
- Jaw clenching and tension
- Pupil dilation
- Mild nausea early in onset
- Fatigue afterward (lasting days)
- "Midweek blues" 2–4 days post-dose
Flag urgently to your clinic or prescribing physician:
- Sustained elevated blood pressure (≥160/100 mmHg) not resolving 1–2 hours post-session
- Persistent elevated heart rate (>120 bpm) at rest 4+ hours post-session
- Severe persistent headache not responding to rest, hydration, analgesia
- Chest pain, shortness of breath, palpitations
- Persistent disorientation or confusion more than 6 hours post-session
- Severe persistent nausea/vomiting preventing oral intake more than 6 hours
- Worsening mood or new/worsening suicidal ideation
- Severe persistent anxiety not resolving within 48–72 hours
For acute psychiatric crisis, call 9-8-8 or go to your nearest emergency department.
Frequently asked questions
How long does each session last? 6–8 hours total in clinic. Onset 30–60 min after dose; peak 1.5–3 hours; comedown 3–5 hours; total experience 4–6 hours plus initial settling and post-session observation.
What should I wear? Comfortable clothes you can lie down in. Layers help — body temperature shifts. Some patients change into more comfortable clothes upon arrival.
Can I bring something meaningful? Yes. Many patients bring a photo, a small object, or a journal. Family photos can be particularly relevant for trauma-focused MDMA-AT work. The therapy team will let you know what's appropriate.
Will I be able to talk during the experience? Yes — and most patients do. This is a distinctive feature of MDMA-AT versus psilocybin or ketamine sessions. The therapy team is actively engaged in conversation; trauma-focused therapeutic work happens in real time during the peak.
Will I have visions or hallucinations? No, generally not. MDMA produces emotional and relational effects rather than the perceptual distortions of classic psychedelics. Some mild perceptual shifts (slight enhancement of colour or sound) are common but not the visions of psilocybin or LSD.
What's the music like? Curated playlists are standard, similar to psilocybin protocols. Music selection is part of the therapeutic frame, supporting emotional opening during the peak.
Why do I have to wear an eye shade? Generally not used as standard during MDMA peaks because patients are conversationally available — eye shades are more associated with the inward-focused psilocybin protocol. Some patients choose to use them at certain points; not required.
What if I need to use the bathroom? Bathrooms are accessible. The therapy team will support you if needed during peak.
What if I have a difficult experience? Difficult experiences are possible but typically less common than with classic psychedelics because of MDMA's emotional warmth. The therapy team is actively present and engaged; integration sessions process challenging content. See MDMA-Assisted Therapy Side Effects and Safety.
Why can't I drive? Residual effects on perception, judgment, and reaction time persist for hours. The 24-hour no-driving rule is universal across published clinical protocols.
What's the overnight stay about? Some Lykos Phase 3 protocols included overnight clinic stays after the first dose for additional monitoring during recovery sleep. Specific Canadian SAP-pathway protocols vary.
When do I do integration? The first integration session is typically 24–72 hours after dosing. Three integration sessions follow each of the three dosing days (9 total integration sessions across the program).
Can my partner or family attend? Most published protocols use therapist-only support during dosing. Some clinical settings accommodate family presence in specific roles, particularly for couples therapy with PTSD (Monson 2020 ARROW model). Discuss at intake.
What if I don't have a designated driver? You cannot do the session without arranged transport home (or overnight stay). Rideshare with a known person, family/friend, or hospice transport (where applicable) are alternatives. Public transit alone is not appropriate.
How do the three sessions build on each other? Each dosing session typically deepens the trauma-processing work. The first session often involves initial trauma engagement; subsequent sessions allow more focused work on specific traumatic content. The therapy team adjusts approach across sessions based on what emerged.
Sources
- Mitchell JM, et al. (2021). MDMA-assisted therapy for severe PTSD: MAPP1 Phase 3. Nat Med. https://pubmed.ncbi.nlm.nih.gov/33972795/
- Mitchell JM, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: MAPP2 Phase 3. Nat Med. https://pubmed.ncbi.nlm.nih.gov/37709999/
- Mithoefer MC, et al. (2018). Phase 2 RCT in military veterans, firefighters, police. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
- Monson CM, et al. (2020). MDMA-AT with cognitive-behavioural conjoint therapy. Eur J Psychotraumatol.
- Government of Canada — 9-8-8 Suicide Crisis Helpline: https://988.ca/
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Related articles in this cluster
- MDMA-Assisted Therapy in Canada
- What Is MDMA-Assisted Therapy?
- MDMA-Assisted Therapy Side Effects and Safety
- How to Access MDMA-Assisted Therapy in Canada (SAP)
- MDMA-Assisted Therapy for PTSD
- What to Expect at a Psilocybin Session
Last updated: 2026-05-06